CRISPR Therapeutics AG Forecast, price target & analysts
Why the stock moved Beta
CRISPR Therapeutics AG Target price 2025 - Analyst rating & recommendation
CRISPR Therapeutics AG Classifications & Recommendation:
CRISPR Therapeutics AG Price Target
| Target Price | $77.52 |
| Price | $55.99 |
| Potential |
38.45%
register free of charge
|
| Number of Estimates | 28 |
|
28 Analysts have issued a price target CRISPR Therapeutics AG 2026 .
The average CRISPR Therapeutics AG target price is $77.52.
This is
38.45%
register free of charge
$281.40
402.59%
register free of charge
$32.32
42.28%
register free of charge
|
|
| A rating was issued by 36 analysts: 22 Analysts recommend CRISPR Therapeutics AG to buy, 13 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the CRISPR Therapeutics AG stock has an average upside potential 2026 of
38.45%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 37.31 | 29.65 |
| 89.95% | 20.53% | |
| EBITDA Margin | -1,198.90% | -1,931.08% |
| 2,095.58% | 61.07% | |
| Net Margin | -981.64% | -1,999.37% |
| 2,272.21% | 103.68% |
30 Analysts have issued a sales forecast CRISPR Therapeutics AG 2025 . The average CRISPR Therapeutics AG sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an CRISPR Therapeutics AG EBITDA forecast 2025. The average CRISPR Therapeutics AG EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
31 CRISPR Therapeutics AG Analysts have issued a net profit forecast 2025. The average CRISPR Therapeutics AG net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.34 | -6.32 |
| 123.71% | 45.62% | |
| P/E | negative | |
| EV/Sales | 115.34 |
31 Analysts have issued a CRISPR Therapeutics AG forecast for earnings per share. The average CRISPR Therapeutics AG EPS is
This results in the following potential growth metrics and future valuations:
CRISPR Therapeutics AG...
Current CRISPR Therapeutics AG Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 26 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 12 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 26 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 12 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Nov 11 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 11 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Oct 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
